Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	Cantor Fitzgerald biotech to hold analyst/industry dinner meeting » 16:34 06/02/23 06/02 16:34 06/02/23 16:34 ASND Ascendis Pharma $91.27 / +3.36 (+3.82%) , ZYME Zymeworks $8.67 / +0.18 (+2.12%) , BCYC Bicycle Therapeutics $25.23 / +1.105 (+4.58%) , IOVA Iovance Biotherapeutics $8.80 / +0.07 (+0.80%) , KURA Kura Oncology $13.19 / -0.3 (-2.22%) , PFE Pfizer $38.36 / +0.325 (+0.85%) , ARVN Arvinas $23.24 / +1.505 (+6.92%) , RHHBY Roche $40.39 / +0.42 (+1.05%) , SNY Sanofi $51.01 / +0.59 (+1.17%) , AZN AstraZeneca $72.57 / -0.27 (-0.37%) , LLY Eli Lilly $441.99 / +5.515 (+1.26%) , ALXO ALX Oncology $8.34 / +0.965 (+13.09%) , PRTG Portage Biotech $3.64 / -0.07 (-1.89%) Biotech Analyst Watsek… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 5th, 16:34 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ZYME SNY RHHBY PFE LLY KURA IOVA BCYC AZN ASND ARVN ALXO ZYME Zymeworks $8.67 / +0.18 (+2.12%) 05/18/23 Zymeworks president, COO Neil Klompas departs 03/30/23 Zymeworks discloses $1.6M purchase of common stock by Ecor1 Capital 01/23/23 Zymeworks shareholder EcoR1 Capital buys $3.0M in company shares 01/19/23 Jazz Pharmaceuticals, Zymeworks report 84% survival for zanidatamab in mGEA SNY Sanofi $51.01 / +0.59 (+1.17%) 05/31/23 Sanofi announces new data on frexalimab, to present at 2023 CMSC 05/21/23 Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results 05/18/23 Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims 05/18/23 Supreme Court upholds Sanofi PCSK9 drug patent victory over Amgen RHHBY Roche $40.39 / +0.42 (+1.05%) 05/17/23 Genentech announces fenebrutinib study met primary, secondary endpoint 05/09/23 Genentech announces FDA acceptance of Vabysmo sBLA 04/26/23 Roche reports CHMP recommends EU approval of fixed-duration Columvi 04/26/23 Zentalis enters agreements with Foundation Medicine, Roche PFE Pfizer $38.36 / +0.325 (+0.85%) 06/01/23 Pfizer announces results from Phase 3 program of REVISIT, ASSEMBLE studies 05/31/23 Pfizer says FDA approves RSV prevention vaccine 05/30/23 Seagen shareholders approve acquisition by Pfizer 05/30/23 Pfizer's marstacimab shows significant efficacy in Phase 3 hemophilia trial LLY Eli Lilly $441.99 / +5.515 (+1.26%) 05/26/23 Attorneys announce over $500M pact with Eli Lilly to settle class-action suit 05/23/23 Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare 05/18/23 Eli Lilly announces detailed results from peresolimab study published in NEJM 05/03/23 Biogen slips after competitor Eli Lilly's Alzheimer's trial hits target KURA Kura Oncology $13.19 / -0.3 (-2.22%) 04/17/23 Kura reports preclinical data on use of farnesyl transferase inhibitors 02/09/23 Kura Oncology announces first patients dosed in Phase 2 trial of ziftomenib 01/24/23 Kura Oncology jumps 6% to $14.85 as FDA clears its IND application for KO-2806 01/24/23 Kura Oncology announces FDA clearance of IND application for KO-2806 IOVA Iovance Biotherapeutics $8.80 / +0.07 (+0.80%) 05/26/23 Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel 03/24/23 Iovance Biotherapeutics completes BLA submission for lifileucel 03/10/23 Iovance says it does not hold deposits, securities at Silicon Valley Bank 01/23/23 Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M BCYC Bicycle Therapeutics $25.23 / +1.105 (+4.58%) 05/11/23 Bicycle Therapeutics and Orano Med report radio-conjugate data results 05/10/23 Bicycle Therapeutics jumps 8% after Bayer oncology pact, milestone payment 05/10/23 Bicycle to receive $45M upfront, plus future milestones in Bayer oncology pact 04/03/23 Bicycle Therapeutics names Santiago Arroyo, M.D Chief Development Officer AZN AstraZeneca $72.57 / -0.27 (-0.37%) 06/02/23 AstraZeneca's IMFINZI plus chemo improved pathologic response in Phase III trial 06/02/23 AstraZeneca says Imfinzi plus chemotherapy showed clinical benefit in trial 06/01/23 AstraZeneca, Merck announce LYNPARZA + abiraterone approved for BRCAm cancer 06/01/23 Merck and AstraZeneca's Lynparza prostate cancer combination approved by FDA ASND Ascendis Pharma $91.27 / +3.36 (+3.82%) 05/31/23 Ascendis Pharma announces oncology program update 05/01/23 Ascendis Pharma receives FDA CRL for TransCon PTH in hypoparathyroidism 04/03/23 Ascendis Pharma falls 38% after disclosing FDA notice of deficiencies in NDA 04/03/23 Ascendis' Phase 1/2 initial trial results of TransCon accepted for ASCO 2023 ARVN Arvinas $23.24 / +1.505 (+6.92%) 05/05/23 Arvinas expects cash to fund requirements into 2026 04/03/23 Arvinas appoints Page as SVP, Global Head of Oncology Strategy, Program Leader 02/23/23 Arvinas expects cash to fund requirements into 2026 12/16/22 Arvinas appoints Everett Cunningham to board of directors ALXO ALX Oncology $8.34 / +0.965 (+13.09%) 05/11/23 ALX Oncology expects cash to fund operations through mid-2025 05/09/23 ALX Oncology announces first patient dosed in Phase 2 trial of evorpacept 04/25/23 ALX Oncology enters clinical trial collaboration with Sanofi 03/13/23 ALX Oncology, Quantum Leap dose first patient in I-SPY-P1 trial ASND ZYME BCYC IOVA KURA PFE ARVN RHHBY SNY AZN LLY ALXO PRTG ASND Ascendis Pharma $91.27 / +3.36 (+3.82%) 06/02/23 Wedbush Ascendis Pharma price target raised to $187 from $186 at Wedbush 05/08/23 Wedbush Ascendis Pharma added to Best Ideas List at Wedbush 04/28/23 Cantor Fitzgerald Ascendis Pharma price target raised to $152 from $142 at Cantor Fitzgerald 04/12/23 Morgan Stanley Ascendis Pharma price target lowered to $107 from $108 at Morgan Stanley ZYME Zymeworks $8.67 / +0.18 (+2.12%) 05/18/23 Citi Zymeworks price target raised to $18 from $17 at Citi 05/09/23 Stifel Zymeworks price target raised to $19 from $18 at Stifel 03/20/23 Wells Fargo Zymeworks coverage transferred at Wells Fargo with Overweight rating 03/10/23 Citi Zymeworks price target lowered to $17 from $21 at Citi BCYC Bicycle Therapeutics $25.23 / +1.105 (+4.58%) 01/04/23 EF Hutton Bicycle Therapeutics initiated with a Buy at EF Hutton 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks 11/10/22 Piper Sandler Bicycle Therapeutics price target raised to $48 from $37 at Piper Sandler 11/09/22 JMP Securities Bicycle Therapeutics price target lowered to $46 from $70 at JMP Securities IOVA Iovance Biotherapeutics $8.80 / +0.07 (+0.80%) 05/30/23 Wells Fargo Iovance upgraded to Overweight at Wells Fargo after lifileucel BLA accepted 05/30/23 Wells Fargo Iovance Biotherapeutics upgraded to Overweight from Equal Weight at Wells Fargo 05/30/23 Stifel Iovance Biotherapeutics price target raised to $24 from $21 at Stifel 05/29/23 Barclays Iovance news 'important clearing event' for shares, says Barclays KURA Kura Oncology $13.19 / -0.3 (-2.22%) 05/31/23 Barclays Barclays reveals two small cap ideas into ASCO conference 05/16/23 BTIG Kura Oncology initiated with a Buy at BTIG 05/11/23 Stifel Kura Oncology price target lowered to $24 from $25 at Stifel 04/17/23 H.C. Wainwright Kura Oncology data support KO-2806 combination studies, says H.C. Wainwright PFE Pfizer $38.36 / +0.325 (+0.85%) 05/23/23 Jefferies Jefferies says Pfizer oral GLP-1 safety and tolerability 'important to note' 05/22/23 Pfizer weight loss drug may be as effective, quicker than Ozempic, CNBC says 05/19/23 BofA AdComm support for Pfizer's infant RSV vaccine 'not surprising,' says BofA 05/16/23 Stifel Seagen likely to stay 'distanced' from deal price after FTC action, says Stifel ARVN Arvinas $23.24 / +1.505 (+6.92%) 05/08/23 Stifel Arvinas price target lowered to $72 from $75 at Stifel 03/18/23 Citi Arvinas price target raised to $77 from $72 at Citi 02/23/23 Capital One Arvinas remains one of the best biotechs to own, says Capital One 01/17/23 Truist Arvinas price target lowered to $65 from $100 at Truist RHHBY Roche $40.39 / +0.42 (+1.05%) 05/19/23 Piper Sandler Regeneron Q1 Eylea miss 'not about share, says Piper Sandler 05/08/23 Guggenheim Regeneron price target lowered to $935 from $960 at Guggenheim 04/10/23 BofA BofA questions relevance of Briumvi tracking to Q1 beat, says TG move 'overdone' 03/27/23 Barclays Roche downgraded to Equal Weight from Overweight at Barclays SNY Sanofi $51.01 / +0.59 (+1.17%) 05/04/23 Raymond James Kymera Therapeutics upgraded to Outperform from Market Perform at Raymond James 04/28/23 Deutsche Bank Sanofi downgraded to Sell from Hold at Deutsche Bank 04/28/23 Deutsche Bank Sanofi downgraded to Sell from Hold at Deutsche Bank AZN AstraZeneca $72.57 / -0.27 (-0.37%) 05/26/23 Argus AstraZeneca price target lowered to $80 from $85 at Argus 05/09/23 Berenberg AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg 04/28/23 JPMorgan AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan 04/13/23 Argus AstraZeneca price target raised to $85 from $75 at Argus LLY Eli Lilly $441.99 / +5.515 (+1.26%) 05/26/23 Wells Fargo Eli Lilly price target raised to $500 from $440 at Wells Fargo 05/24/23 BofA Eli Lilly price target raised to $500 from $450 at BofA 05/23/23 TD Cowen Eli Lilly price target raised to $500 from $430 at TD Cowen 05/19/23 JPMorgan JPMorgan places 'Negative Catalyst Watch' on Novartis into data ALXO ALX Oncology $8.34 / +0.965 (+13.09%) 03/14/23 UBS ALX Oncology price target lowered to $29 from $31 at UBS 03/10/23 H.C. Wainwright ALX Oncology price target lowered to $30 from $65 at H.C. Wainwright 11/09/22 Cantor Fitzgerald ALX Oncology price target lowered to $22 from $32 at Cantor Fitzgerald 11/09/22 H.C. Wainwright ALX Oncology price target lowered to $65 from $80 at H.C. Wainwright PRTG Portage Biotech $3.64 / -0.07 (-1.89%) 12/01/22 H.C. Wainwright Portage Biotech price target lowered to $21 from $22 at H.C. Wainwright 11/30/22 Cantor Fitzgerald Portage Biotech price target lowered to $18 from $26 at Cantor Fitzgerald 11/30/22 Oppenheimer Portage Biotech price target lowered to $18 from $26 at Oppenheimer 09/20/22 H.C. Wainwright Portage Biotech price target lowered to $22 from $32 at H.C. Wainwright ZYME SNY RHHBY PRTG PFE LLY KURA IOVA BCYC AZN ARVN ALXO ZYME Zymeworks $8.67 / +0.18 (+2.12%) 05/08/23 Zymeworks reports Q1 adjusted EPS (34c), consensus (54c) 03/07/23 Zymeworks reports Q4 EPS $4.65, consensus $4.84 SNY Sanofi $51.01 / +0.59 (+1.17%) 04/27/23 Sanofi confirms FY23 business EPS view of up low single digits at CER 04/27/23 Sanofi reports Q1 business EPS EUR 2.16, up 11.9% at CER 03/30/23 IGM Biosciences Sanofi sees FY23 revenue $3M, consensus $5.5M 02/03/23 Sanofi sees 2023 business EPS up at low single digit rate at CER RHHBY Roche $40.39 / +0.42 (+1.05%) 04/26/23 Roche confirms outlook for FY23 04/26/23 Roche reports Q1 group sales CHF 15.32B vs. CHF 16.45B last year 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year PRTG Portage Biotech $3.64 / -0.07 (-1.89%) 03/01/23 Portage Biotech reports Q4 EPS (44c), consensus (23c) PFE Pfizer $38.36 / +0.325 (+0.85%) 05/02/23 Pfizer backs FY23 adjusted EPS view $3.25-$3.45, consensus $3.36 05/02/23 Pfizer reports Q1 adjusted EPS $1.23, consensus 98c 03/15/23 Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B 01/31/23 Pfizer sees FY23 adjusted EPS $3.25-$3.45, consensus $4.44 LLY Eli Lilly $441.99 / +5.515 (+1.26%) 04/27/23 Eli Lilly raises FY23 adjusted EPS view to $8.65-$8.85 from $8.35-$8.55 04/27/23 Eli Lilly reports Q1 EPS $1.62, consensus $1.73 04/26/23 Notable companies reporting before tomorrow's open KURA Kura Oncology $13.19 / -0.3 (-2.22%) 02/23/23 Kura Oncology reports Q4 EPS (49c), consensus (57c) IOVA Iovance Biotherapeutics $8.80 / +0.07 (+0.80%) 05/09/23 Iovance Biotherapeutics reports Q1 EPS (50c), consensus (74c) 02/28/23 Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c) BCYC Bicycle Therapeutics $25.23 / +1.105 (+4.58%) 05/04/23 Bicycle Therapeutics reports Q1 EPS ($1.30), consensus ($1.07) 02/28/23 Bicycle Therapeutics reports Q4 EPS ($1.01), consensus ($1.06) AZN AstraZeneca $72.57 / -0.27 (-0.37%) 04/27/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 04/27/23 AstraZeneca reports Q1 core EPS $1.92, consensus $1.07 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 ARVN Arvinas $23.24 / +1.505 (+6.92%) 05/05/23 Arvinas reports Q1 EPS ($1.54), consensus ($1.51) 02/23/23 Arvinas reports Q4 EPS ($1.56), consensus ($1.22) ALXO ALX Oncology $8.34 / +0.965 (+13.09%) 05/11/23 ALX Oncology reports Q1 EPS (74c), consensus (80c) SNY RHHBY PFE LLY AZN SNY Sanofi $51.01 / +0.59 (+1.17%) 04/12/23 Sanders to call CEOs of largest insulin makers to testify, STAT says 01/30/23 Sanofi plans to lay off staff at vaccine factories in India, Reuters says 01/23/23 CytoReason to license IBD disease model to Sanofi 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports RHHBY Roche $40.39 / +0.42 (+1.05%) 05/10/23 BioNTech data was reported in June 2022, Reuters reports 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports PFE Pfizer $38.36 / +0.325 (+0.85%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 China's new Covid surge could result in 65M infections a week, Bloomberg says 05/14/23 Pfizer Pfizer, Stryker have strong growth prospects, Barron's says 05/10/23 BioNTech pancreatic cancer vaccine 'shows promise' in small trial, NYT says LLY Eli Lilly $441.99 / +5.515 (+1.26%) 04/24/23 Novo Nordisk, Lilly lobby for Medicare coverage of weight-loss drug, WSJ report 04/11/23 Drugmakers call for abortion pill ruling reversal, Reuters reports 04/10/23 Weight-loss business upended by popularity of ozempic, other drugs, WSJ reports AZN AstraZeneca $72.57 / -0.27 (-0.37%) 05/19/23 Astra China head says company seeks to 'love the Communist Party,' Reuters says 05/04/23 AstraZeneca chair says increasing CEO's pay wards of rivals, FT reports 04/06/23 GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says ZYME SNY RHHBY PFE LLY KURA IOVA AZN ASND ZYME Zymeworks $8.67 / +0.18 (+2.12%) 03/08/23 Fly Intel: Pre-market Movers 01/12/23 Fly Intel: After-Hours Movers 12/19/22 What You Missed On Wall Street On Monday 12/19/22 What You Missed On Wall Street This Morning SNY Sanofi $51.01 / +0.59 (+1.17%) 05/10/23 What Wall Street is saying about Disney ahead of earnings 03/23/23 What You Missed On Wall Street On Thursday 03/23/23 What You Missed On Wall Street This Morning 03/14/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations RHHBY Roche $40.39 / +0.42 (+1.05%) 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover PFE Pfizer $38.36 / +0.325 (+0.85%) 05/16/23 What You Missed On Wall Street On Tuesday 05/02/23 What You Missed On Wall Street On Tuesday 05/02/23 What You Missed On Wall Street This Morning 03/21/23 What You Missed On Wall Street On Tuesday LLY Eli Lilly $441.99 / +5.515 (+1.26%) 05/03/23 What You Missed On Wall Street On Wednesday 05/03/23 What You Missed On Wall Street This Morning 05/03/23 Fly Intel: Pre-market Movers 04/27/23 What You Missed On Wall Street On Thursday KURA Kura Oncology $13.19 / -0.3 (-2.22%) 05/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/21/23 Biotech Alert: Searches spiking for these stocks today IOVA Iovance Biotherapeutics $8.80 / +0.07 (+0.80%) 06/02/23 Biotech Alert: Searches spiking for these stocks today 06/01/23 Biotech Alert: Searches spiking for these stocks today 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning AZN AstraZeneca $72.57 / -0.27 (-0.37%) 04/11/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/05/23 What You Missed On Wall Street On Wednesday 04/05/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street This Morning ASND Ascendis Pharma $91.27 / +3.36 (+3.82%) 05/04/23 Biotech Alert: Searches spiking for these stocks today 05/03/23 Biotech Alert: Searches spiking for these stocks today 04/06/23 Biotech Alert: Searches spiking for these stocks today 04/05/23 Biotech Alert: Searches spiking for these stocks today 06/02/23 Biotechnology--Pre-ASCO Reception 06/12/23 Biotech/Biopharma 06/28/23 Biotech/Biopharma 06/28/23 Biotech/Biopharma 08/02/23 Biotech/Biopharma 06/02/23 2023 ASCO Annual Meeting 06/02/23 Truist Hosted Company Events at 2023 ASCO Annual Meeting 08/08/23 Eli Lilly - LLY 07/01/23 PDUFA Date for Glofitamab 11/25/23 PDUFA Date for Lifileucel 12/22/23 PDUFA Date for Eplontersen 06/06/23 Iovance Biotherapeutics, Inc. 06/12/23 Kura Oncology 06/15/23 Arvinas, Inc. 06/16/23 ALX Oncology Holdings Inc. 06/27/23 Bicycle Therapeutics PFE LLY AZN PFE Pfizer $38.36 / +0.325 (+0.85%) 05/24/23 Notable open interest changes for May 24th 05/23/23 Unusually active option classes on open May 23rd 05/23/23 Notable open interest changes for May 23rd 05/23/23 Unusual call flow in option market yesterday LLY Eli Lilly $441.99 / +5.515 (+1.26%) 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th AZN AstraZeneca $72.57 / -0.27 (-0.37%) 05/26/23 Unusually active option classes on open May 26th 05/18/23 Unusually active option classes on open May 18th 05/09/23 AstraZeneca put volume heavy and directionally bearish 04/27/23 Unusually active option classes on open April 27th
Conference/Events	Kura Oncology to host investor day » 16:27 06/02/23 06/02 16:27 06/02/23 16:27 KURA Kura Oncology $13.19 / -0.3 (-2.22%) Investor Day to be held… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 5th, 16:27 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KURA Kura Oncology $13.19 / -0.3 (-2.22%) 04/17/23 Kura reports preclinical data on use of farnesyl transferase inhibitors 02/09/23 Kura Oncology announces first patients dosed in Phase 2 trial of ziftomenib 01/24/23 Kura Oncology jumps 6% to $14.85 as FDA clears its IND application for KO-2806 01/24/23 Kura Oncology announces FDA clearance of IND application for KO-2806 KURA Kura Oncology $13.19 / -0.3 (-2.22%) 05/31/23 Barclays Barclays reveals two small cap ideas into ASCO conference 05/16/23 BTIG Kura Oncology initiated with a Buy at BTIG 05/11/23 Stifel Kura Oncology price target lowered to $24 from $25 at Stifel 04/17/23 H.C. Wainwright Kura Oncology data support KO-2806 combination studies, says H.C. Wainwright KURA Kura Oncology $13.19 / -0.3 (-2.22%) 02/23/23 Kura Oncology reports Q4 EPS (49c), consensus (57c) KURA Kura Oncology $13.19 / -0.3 (-2.22%) 05/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/21/23 Biotech Alert: Searches spiking for these stocks today 06/12/23 Biotech/Biopharma

Thursday
Recommendations	Travere Therapeutics price target raised to $35 from $22 at H.C. Wainwright » 11:15 06/01/23 06/01 11:15 06/01/23 11:15 TVTX Travere Therapeutics $17.88 / +0.01 (+0.06%) H.C. Wainwright raised… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly TVTX Travere Therapeutics $17.88 / +0.01 (+0.06%) 05/31/23 Travere Therapeutics announces results from cohort 6 of Phase 1/2 COMPOSE study 05/01/23 Travere Therapeutics down 24% at $17.25 after announcing sparsentan study data 05/01/23 Travere Therapeutics' sparsentan study did not achieve primary efficacy 04/02/23 Travere Therapeutics announces interim analysis from Phase 3 PROTECT study TVTX Travere Therapeutics $17.88 / +0.01 (+0.06%) 05/22/23 TD Cowen Travere initiated with Outperform, $30 target at TD Cowen 05/22/23 TD Cowen Travere Therapeutics initiated with an Outperform at TD Cowen 05/09/23 Canaccord Travere Therapeutics price target lowered to $37 from $42 at Canaccord TVTX Travere Therapeutics $17.88 / +0.01 (+0.06%) 05/04/23 Travere Therapeutics reports Q2 adjusted EPS (82c), consensus ($1.17) 02/23/23 Travere Therapeutics reports Q4 EPS ($1.03), consensus ($1.07) 01/09/23 Travere Therapeutics sees Q4 net product sales $52M, consensus $57.15 01 Mar TVTX Travere Therapeutics $17.88 / +0.01 (+0.06%) 05/02/23 What You Missed On Wall Street On Tuesday 05/02/23 What You Missed On Wall Street This Morning 05/01/23 Fly Intel: After-Hours Movers 02/21/23 What You Missed On Wall Street On Tuesday

Wednesday
Hot Stocks	Travere Therapeutics announces results from cohort 6 of Phase 1/2 COMPOSE study » 07:11 05/31/23 05/31 07:11 05/31/23 07:11 TVTX Travere Therapeutics $16.42 / -0.01 (-0.06%) Travere Therapeutics… Travere Therapeutics announced positive results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated for the treatment of classical homocystinuria. In this cohort, five patients were randomized in a blinded fashion to receive 2.5 mg/kg of lyophilized pegtibatinase or placebo twice weekly, with four patients assigned to the treatment group. To date in the study, pegtibatinase has been generally well-tolerated. "The results from cohort 6 in the Phase 1/2 COMPOSE Study build upon the dose dependent response observed in cohorts 1-5 and continue to demonstrate pegtibatinase has the potential to improve overall metabolic function in patients living with classical homocystinuria, a rare and devastating disease," said William Rote, Ph.D., senior vice president of research and development at Travere Therapeutics. "Our goal is to deliver pegtibatinase as the first disease-modifying treatment option for the HCU community and today we are one step closer. We look forward to continuing to engage with regulators to further refine our plans for a potential pivotal Phase 3 study which is expected to initiate by year-end." Key safety findings: There were no reports of treatment-related serious adverse events, anaphylaxis, or discontinuations in the highest dose cohort treated with the 2.5 mg/kg twice weekly dose of pegtibatinase. Two participants receiving 2.5 mg/kg BIW reported moderate injection site reactions associated with urticaria, which resulted in a temporary dose interruption. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly TVTX Travere Therapeutics $16.42 / -0.01 (-0.06%) 05/01/23 Travere Therapeutics down 24% at $17.25 after announcing sparsentan study data 05/01/23 Travere Therapeutics' sparsentan study did not achieve primary efficacy 04/02/23 Travere Therapeutics announces interim analysis from Phase 3 PROTECT study 02/17/23 Ligand's partner Travere Therapeutics gets FDA accelerated approval of Filspari TVTX Travere Therapeutics $16.42 / -0.01 (-0.06%) 05/22/23 TD Cowen Travere initiated with Outperform, $30 target at TD Cowen 05/22/23 TD Cowen Travere Therapeutics initiated with an Outperform at TD Cowen 05/09/23 Canaccord Travere Therapeutics price target lowered to $37 from $42 at Canaccord TVTX Travere Therapeutics $16.42 / -0.01 (-0.06%) 05/04/23 Travere Therapeutics reports Q2 adjusted EPS (82c), consensus ($1.17) 02/23/23 Travere Therapeutics reports Q4 EPS ($1.03), consensus ($1.07) 01/09/23 Travere Therapeutics sees Q4 net product sales $52M, consensus $57.15 01 Mar TVTX Travere Therapeutics $16.42 / -0.01 (-0.06%) 05/02/23 What You Missed On Wall Street On Tuesday 05/02/23 What You Missed On Wall Street This Morning 05/01/23 Fly Intel: After-Hours Movers 02/21/23 What You Missed On Wall Street On Tuesday
Recommendations	Barclays reveals two small cap ideas into ASCO conference » 05:55 05/31/23 05/31 05:55 05/31/23 05:55 RCUS Arcus Biosciences $20.26 / -1.71 (-7.78%) , KURA Kura Oncology $13.22 / -0.155 (-1.16%) Barclays reveled two… Barclays reveled two stock ideas going into this weekend's American Society of Clinical Oncology meeting: Arcus Biosciences (RCUS) and Kura Oncology (KURA). On Acrus, the analyst is positive on the stock's near-term risk/reward, including upcoming data, and sees an attractive valuation. The firm believes ASCO abstracts last week have helped shift the negative sentiment around anti-TIGIT. For Kura, Barclays is positive on the stock's near-term risk/reward and sees it potentially closing the gap versus Syndax. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events RCUS KURA RCUS Arcus Biosciences $20.26 / -1.71 (-7.78%) 05/26/23 Arcus Biosciences rises 25.4% 05/26/23 Arcus Biosciences rises 22.6% 05/26/23 Arcus Biosciences rises 20.6% 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead KURA Kura Oncology $13.22 / -0.155 (-1.16%) 04/17/23 Kura reports preclinical data on use of farnesyl transferase inhibitors 02/09/23 Kura Oncology announces first patients dosed in Phase 2 trial of ziftomenib 01/24/23 Kura Oncology jumps 6% to $14.85 as FDA clears its IND application for KO-2806 01/24/23 Kura Oncology announces FDA clearance of IND application for KO-2806 RCUS KURA RCUS Arcus Biosciences $20.26 / -1.71 (-7.78%) 05/26/23 Citi Arcus Biosciences price target raised to $41 from $40 at Citi 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi 12/21/22 Barclays Arcus Biosciences price target lowered to $36 from $60 at Barclays KURA Kura Oncology $13.22 / -0.155 (-1.16%) 05/16/23 BTIG Kura Oncology initiated with a Buy at BTIG 05/11/23 Stifel Kura Oncology price target lowered to $24 from $25 at Stifel 04/17/23 H.C. Wainwright Kura Oncology data support KO-2806 combination studies, says H.C. Wainwright 01/30/23 Stifel Kura Oncology initiated with a Buy at Stifel RCUS KURA RCUS Arcus Biosciences $20.26 / -1.71 (-7.78%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) KURA Kura Oncology $13.22 / -0.155 (-1.16%) 02/23/23 Kura Oncology reports Q4 EPS (49c), consensus (57c) RCUS KURA RCUS Arcus Biosciences $20.26 / -1.71 (-7.78%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers KURA Kura Oncology $13.22 / -0.155 (-1.16%) 05/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/21/23 Biotech Alert: Searches spiking for these stocks today 06/12/23 Biotech/Biopharma 06/02/23 2023 ASCO Annual Meeting 05/31/23 Kura Oncology, Inc. 06/15/23 Arcus Biosciences, Inc.

Tuesday
Options	Largest borrow rate increases among liquid names » 08:45 05/30/23 05/30 08:45 05/30/23 08:45 FRCB First Republic Bank / + , CIFR Cipher Mining $2.40 / +0.1 (+4.36%) , NKLA Nikola / + , RAIN Rain Oncology $1.10 / -0.04 (-3.51%) , RXDX Prometheus $198.53 / -0.07 (-0.04%) , MVST Microvast $1.37 / -0.045 (-3.19%) , ATOM Atomera $9.90 / +0.41 (+4.32%) , XBI SPDR S&P BIOTECH $84.26 / +0.75 (+0.90%) , JWN Nordstrom $16.03 / +0.82 (+5.39%) , RUM Rumble $9.56 / -0.36 (-3.63%) Latest data shows the… Latest data shows the largest indicative borrow rate increases among liquid option names include: First Republic Bank (FRCB) 42.75% +17.11, Cipher Mining (CIFR) 45.84% +11.33, Nikola (NKLA) 83.45% +5.61, Rain Therapeutics (RAIN) 15.69% +3.43, Prometheus Biosciences (RXDX) 3.67% +3.41, Microvast Holdings (MVST) 5.17% +2.44, Atomera (ATOM) 11.22% +2.23, SPDR S&P Biotech (XBI) 6.07% +2.07, Nordstrom (JWN) 4.68% +1.98, and Rumble (RUM) 37.69% +1.94. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RXDX RUM RAIN NKLA MVST JWN FRCB CIFR ATOM RXDX Prometheus $198.53 / -0.07 (-0.04%) 05/16/23 Prometheus, Seagen slip after FTC sues to block Horizon acquisition 04/16/23 Fly Intel: Top five weekend stock stories 04/16/23 Merck acquires Prometheus Biosciences for $200 per share 12/07/22 Prometheus announces results for PRA023 in APOLLO-CD Phase 2 study RUM Rumble $9.56 / -0.36 (-3.63%) 05/18/23 Rumble launches alpha release of Creator Sponsorship Marketplace 05/16/23 Culper Research calls Rumble 'unraveling stock promotion', remains short 04/27/23 Rumble down 4% to $7.81 after Culper Research short report 04/12/23 Rumble partners with RNC to stream first GOP debate of 2024 primaries RAIN Rain Oncology $1.10 / -0.04 (-3.51%) 05/30/23 Rain Oncology cofounder Robert Doebele to assume role of CMO 05/30/23 Rain Oncology provides update, outlines priorities for milademetan program 05/22/23 Rain Oncology Phase 3 MANTRA trial did not meet primary endpoint 01/23/23 Rain Oncology announces publication of Phase 1 data of milademetan NKLA Nikola / + 05/25/23 Nikola under pressure after receiving delisting notice 05/24/23 Nikola encourages stockholders to vote for Proposal 2 05/09/23 Nikola shares plunge 15% after quarterly report, exit from European JV 05/09/23 Nikola: Coolidge Phase 2 assembly hall expansion on track for end of Q2 MVST Microvast $1.37 / -0.045 (-3.19%) 04/13/23 Microvast announces appointment of Isida Tushe as general counsel 03/15/23 Microvast selected by MAFI & TREPEL as battery supplier for EV tractors 12/07/22 Microvast secures contract to supply BESS to U.S. customer JWN Nordstrom $16.03 / +0.82 (+5.39%) 05/10/23 Nordstrom names Cathy Smith as CFO, effective May 29 04/17/23 Nordstrom appoints Eric Sprunk to Board of Directors 04/17/23 Tilly's names Laura Janney as EVP, Chief Merchandising Officer 04/14/23 Nordstrom appoints Jason Morris as Chief Technology and Information Officer FRCB First Republic Bank / + 05/25/23 CRE exposure may pressure ratings of regional banks, Fitch Ratings says CIFR Cipher Mining $2.40 / +0.1 (+4.36%) 05/01/23 Cipher Mining mines 406 bitcoin in April 03/20/23 Cipher names Patrick Kelly and Will Iwaschuk co- presidents, Stennett as CAO 01/10/23 Cipher Mining ends 2022 with 394 Bitcoin 12/20/22 Cipher Mining acquires additional new mining rigs for Odessa data center ATOM Atomera $9.90 / +0.41 (+4.32%) 04/26/23 Atomera jumps 40% to $7.32 after entering pact with STMicroelectronics 04/26/23 Atomera signs commercial license agreement with STMicroelectronics 03/12/23 Atomera says not materially impacted by Silicon Valley Bank closure 01/12/23 Atomera collaborates with Arizona State over semiconductor material advancement FRCB CIFR NKLA RAIN RXDX MVST ATOM XBI JWN RUM FRCB First Republic Bank / + CIFR Cipher Mining $2.40 / +0.1 (+4.36%) 04/25/23 Canaccord Cipher Mining initiated with a Buy at Canaccord 03/14/23 Cantor Fitzgerald Cipher Mining initiated with an Overweight at Cantor Fitzgerald 03/13/23 Cantor Fitzgerald Cipher Mining initiated with an Overweight at Cantor Fitzgerald 02/21/23 Needham Cipher Mining initiated with a Buy at Needham NKLA Nikola / + 05/10/23 TD Cowen TD Cowen downgrades Nikola to Market Perform on persistent liquidity overhang 05/09/23 TD Cowen Nikola downgraded to Market Perform from Outperform at TD Cowen 03/31/23 BTIG BTIG downgrades Nikola to Neutral after stock offering, expects further dilution 03/31/23 BTIG Nikola downgraded to Neutral from Buy at BTIG RAIN Rain Oncology $1.10 / -0.04 (-3.51%) 05/23/23 H.C. Wainwright Rain Oncology downgraded to Neutral from Buy at H.C. Wainwright 05/23/23 Oppenheimer Rain Oncology downgraded to Perform on Phase 3 failure at Oppenheimer 05/23/23 Citi Rain Oncology downgraded to Neutral from Buy at Citi 05/22/23 Oppenheimer Rain Oncology downgraded to Perform from Outperform at Oppenheimer RXDX Prometheus $198.53 / -0.07 (-0.04%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital 04/17/23 Credit Suisse Prometheus downgraded to Neutral from Outperform at Credit Suisse MVST Microvast $1.37 / -0.045 (-3.19%) 04/03/23 H.C. Wainwright Microvast initiated with a Buy at H.C. Wainwright 08/18/22 Oppenheimer Oppenheimer starts Microvast with Outperform, $8 price target 08/18/22 Oppenheimer Microvast initiated with an Outperform at Oppenheimer ATOM Atomera $9.90 / +0.41 (+4.32%) 04/27/23 Craig-Hallum Atomera price target raised to $17 from $13 at Craig-Hallum 11/10/22 Craig-Hallum Atomera price target lowered to $13 from $22 at Craig-Hallum XBI SPDR S&P BIOTECH $84.26 / +0.75 (+0.90%) JWN Nordstrom $16.03 / +0.82 (+5.39%) 05/25/23 Citi Nordstrom price target lowered to $17 from $20 at Citi 05/02/23 Barclays Nordstrom price target lowered to $14 from $16 at Barclays 03/08/23 Argus Nordstrom upgraded to Buy from Hold at Argus 03/03/23 Morgan Stanley Nordstrom assumed with an Underweight at Morgan Stanley RUM Rumble $9.56 / -0.36 (-3.63%) 05/16/23 DA Davidson Rumble price target lowered to $12 from $15 at DA Davidson 12/02/22 Oppenheimer Rumble initiated with a Perform at Oppenheimer RXDX RUM RAIN NKLA MVST JWN CIFR RXDX Prometheus $198.53 / -0.07 (-0.04%) 05/09/23 Prometheus reports Q1 EPS (86c), consensus (91c) 02/28/23 Prometheus reports Q4 EPS (90c), consensus (92c) RUM Rumble $9.56 / -0.36 (-3.63%) 05/16/23 Rumble reports Q1 EPS (14c) vs. (2c) last year 03/30/23 Rumble reports Q4 EPS 0c, two estimates (2c) RAIN Rain Oncology $1.10 / -0.04 (-3.51%) 05/11/23 Rain Oncology reports Q1 EPS (56c), consensus (61c) 03/09/23 Rain Oncology reports Q4 EPS (70c), consensus (56c) NKLA Nikola / + 05/09/23 Nikola reports Q1 adjusted EPS (26c), consensus (26c) 05/08/23 Notable companies reporting before tomorrow's open 02/23/23 Nikola reports Q4 adjusted EPS (37c), consensus (43c) MVST Microvast $1.37 / -0.045 (-3.19%) 05/09/23 Microvast sees Q2 revenue $63M-$67M 05/09/23 Microvast raises FY23 revenue view to $348M-$368M JWN Nordstrom $16.03 / +0.82 (+5.39%) 03/02/23 Nordstrom reports Q4 EPS 74c, consensus 66c 03/02/23 Nordstrom sees FY23 adjusted EPS $1.80-$2.20, consensus $1.93 03/02/23 Notable companies reporting after market close 01/19/23 Nordstrom cuts FY22 adjusted EPS view to $1.50-$1.70 from $2.30-$2.60 CIFR Cipher Mining $2.40 / +0.1 (+4.36%) 05/09/23 Cipher Mining reports Q1 adjusted EPS 3c, consensus (2c) 03/14/23 Cipher Mining reports FY22 adjusted EPS (26c) vs (4c) last year 31 Mar 09 Dec RUM NKLA MVST JWN FRCB RUM Rumble $9.56 / -0.36 (-3.63%) 04/27/23 Culper short Rumble, says unique user base 'fraction' of claimed size 04/27/23 Culper Research announces short position in Rumble 01/05/23 Bear Cave sees 'more problems' at Rumble NKLA Nikola / + 01/20/23 Nikola speculated by The Deal as 'attractive' to activist 12/01/22 Fuzzy Panda short Fisker, says 'asset-light' model really 'liability-heavy' MVST Microvast $1.37 / -0.045 (-3.19%) 05/23/23 U.S. DOE ends plans for $200M grant for Microvast, Reuters reports 02/16/23 DOE reviewing $200M grant to Microvast amid concerns, Bloomberg says JWN Nordstrom $16.03 / +0.82 (+5.39%) 04/19/23 Ryan Cohen pulls Nordstrom board candidates, Bloomberg reports 02/06/23 Nordstrom tells Fox open to Cohen views, hasn't sought talks in 'years' 02/02/23 Ryan Cohen amasses sizable stake in Nordstrom, WSJ reports FRCB First Republic Bank / + 05/25/23 JPMorgan informs some First Republic staff of layoffs, Reuters says 05/24/23 DOJ probing trading by First Republic employees amid collapse, Bloomberg says 05/24/23 DOJ probing trading by First Republic employees amid collapse, Bloomberg says 05/05/23 SEC probing trades by First Republic executives, Bloomberg reports RXDX RUM RAIN NKLA MVST JWN FRCB CIFR ATOM RXDX Prometheus $198.53 / -0.07 (-0.04%) 05/16/23 What You Missed On Wall Street On Tuesday 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street This Morning 04/17/23 Fly Intel: Pre-market Movers RUM Rumble $9.56 / -0.36 (-3.63%) 03/31/23 Fly Intel: Pre-market Movers 03/30/23 Fly Intel: After-Hours Movers 01/05/23 What You Missed On Wall Street This Morning 12/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations RAIN Rain Oncology $1.10 / -0.04 (-3.51%) 05/23/23 What You Missed On Wall Street On Tuesday 05/23/23 What You Missed On Wall Street This Morning 05/23/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/22/23 What You Missed On Wall Street On Monday NKLA Nikola / + 05/15/23 What You Missed This Week in EVs and Clean Energy 05/10/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/09/23 What You Missed On Wall Street On Tuesday 05/09/23 Fly Intel: Pre-market Movers MVST Microvast $1.37 / -0.045 (-3.19%) 05/10/23 What You Missed On Wall Street On Wednesday 05/10/23 What You Missed On Wall Street This Morning 01/30/23 Here's what Wall St. experts are saying about these automakers ahead of earnings JWN Nordstrom $16.03 / +0.82 (+5.39%) 05/07/23 Short Report: Bears increase exposure to Lemonade after earnings-driven spike 04/02/23 Short Report: Bearish views on Lovesac remain elevated despite earnings beat 03/11/23 Buy/Sell: Wall Street's top 10 stock calls this week 03/08/23 What You Missed On Wall Street On Wednesday FRCB First Republic Bank / + 05/26/23 What You Missed On Wall Street On Friday 05/26/23 What You Missed On Wall Street This Morning 05/25/23 What You Missed On Wall Street On Thursday CIFR Cipher Mining $2.40 / +0.1 (+4.36%) 02/07/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ATOM Atomera $9.90 / +0.41 (+4.32%) 04/26/23 Fly Intel: After-Hours Movers 06/02/23 2023 ASCO Annual Meeting 05/31/23 Nordstrom - JWN 05/31/23 Rain Oncology Inc. 06/06/23 Nordstrom Inc. 06/07/23 Nikola Corporation 06/15/23 Prometheus Biosciences, Inc. 06/16/23 Rumble Inc 07/10/23 Prometheus 07/11/23 Prometheus XBI RXDX RUM NKLA MVST JWN CIFR ATOM XBI SPDR S&P BIOTECH $84.26 / +0.75 (+0.90%) 04/21/23 Largest borrow rate increases among liquid names 01/27/23 Largest borrow rate increases among liquid names RXDX Prometheus $198.53 / -0.07 (-0.04%) 12/05/22 Prometheus Biosciences put volume heavy and directionally bearish RUM Rumble $9.56 / -0.36 (-3.63%) 05/26/23 Rumble put volume heavy and directionally bearish 05/24/23 Largest borrow rate increases among liquid names 05/15/23 Rumble options imply 10.0% move in share price post-earnings 05/10/23 Rumble call volume above normal and directionally bullish NKLA Nikola / + 05/22/23 Largest borrow rate increases among liquid names 05/19/23 Unusually active option classes on open May 19th 05/17/23 Largest borrow rate increases among liquid names 05/11/23 Largest borrow rate increases among liquid names MVST Microvast $1.37 / -0.045 (-3.19%) 05/16/23 Largest borrow rate increases among liquid names JWN Nordstrom $16.03 / +0.82 (+5.39%) 05/26/23 Largest borrow rate increases among liquid names 04/25/23 Nordstrom call volume above normal and directionally bullish 04/10/23 Nordstrom call volume above normal and directionally bullish 03/16/23 Nordstrom call volume above normal and directionally bullish CIFR Cipher Mining $2.40 / +0.1 (+4.36%) 05/19/23 Largest borrow rate increases among liquid names 05/18/23 Largest borrow rate increases among liquid names 02/17/23 Largest borrow rate increases among liquid names ATOM Atomera $9.90 / +0.41 (+4.32%) 05/15/23 Largest borrow rate increases among liquid names

Over a week ago
On The Fly	Biotech Alert: Searches spiking for these stocks today » 10:54 05/25/23 05/25 10:54 05/25/23 10:54 KRYS Krystal Biotech $117.51 / -1.31 (-1.10%) , BPMC Blueprint Medicines $55.95 / -2.01 (-3.47%) , RNA Avidity Biosciences $10.98 / -0.315 (-2.79%) , ACHV Achieve Life Sciences $6.03 / +0.02 (+0.33%) , OTLK Outlook Therapeutics $1.46 / -0.04 (-2.68%) These names in the… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events RNA OTLK KRYS BPMC ACHV RNA Avidity Biosciences $10.98 / -0.315 (-2.79%) 05/17/23 Avidity Biosciences: FDA eases partial clinical hold on AOC 1001 04/27/23 Avidity Biosciences announces data from MARINA clinical trial of AOC 1001 04/24/23 Avidity Biosciences granted FDA Fast Track designation to AOC 1044 03/30/23 Avidity Biosciences provides regulatory update on dystrophy candidate AOC 1001 OTLK Outlook Therapeutics $1.46 / -0.04 (-2.68%) 03/13/23 Outlook Therapeutics confirms no exposure to Silivon Valley Bank 02/14/23 Outlook Therapeutics announces anticipated milestones 02/14/23 Outlook sees cash runway through anticipated FDA approval of ONS-5010 01/19/23 Outlook Therapeutics appoints Surendra Sharma as SVP, medical affairs KRYS Krystal Biotech $117.51 / -1.31 (-1.10%) 05/23/23 Krystal Biotech director Janney sells 50,000 common shares 05/23/23 Option Care Health selected by Krystal Biotech as part of Vyjuvek distribution 05/22/23 Krystal Biotech sees cash runway through end of 2026 05/19/23 Krystal Biotech up 5% after receiving FDA approval for Vyjuvek BPMC Blueprint Medicines $55.95 / -2.01 (-3.47%) 05/23/23 Blueprint Medicines announces publication of results from PIONEER Trial 05/22/23 Blueprint Medicines announces FDA approval of AYVAKIT from treatment of SM 05/22/23 Blueprint Medicines' Ayvakit gets expanded approval for ISM 04/26/23 Blueprint Medicines to present new clinical data at 2023 ASCO meeting ACHV Achieve Life Sciences $6.03 / +0.02 (+0.33%) 05/23/23 Achieve Life Sciences' cytisinicline shows smoking cessation benefit in trial 05/17/23 Achieve Life Sciences refinances loan with Silicon Valley Bank 04/20/23 Achieve Life Sciences announces Phase 2 ORCA-V1 trial results 03/30/23 Achieve Life Sciences announces board refresh KRYS BPMC RNA ACHV OTLK KRYS Krystal Biotech $117.51 / -1.31 (-1.10%) 05/25/23 BofA Krystal Biotech price target raised to $140 from $118 at BofA 05/24/23 Alliance Global Partners Abeona 'well positioned' for potential EB-101 approval, says Alliance Global 05/24/23 Stifel Krystal Biotech price target raised to $145 from $102 at Stifel 05/22/23 Guggenheim Krystal Biotech price target raised to $130 from $101 at Guggenheim BPMC Blueprint Medicines $55.95 / -2.01 (-3.47%) 05/23/23 Guggenheim Blueprint Medicines price target raised to $82 from $78 at Guggenheim 05/23/23 H.C. Wainwright Blueprint Medicines price target raised to $85 from $75 at H.C. Wainwright 05/23/23 Barclays Blueprint Medicines price target raised to $46 from $44 at Barclays 05/05/23 H.C. Wainwright Blueprint Medicines price target raised to $75 from $70 at H.C. Wainwright RNA Avidity Biosciences $10.98 / -0.315 (-2.79%) 05/22/23 Evercore ISI Avidity Biosciences upgraded to Outperform from In Line at Evercore ISI 05/11/23 Wells Fargo Avidity Biosciences price target lowered to $50 from $55 at Wells Fargo 03/31/23 Evercore ISI Avidity Biosciences downgraded to In Line at Evercore on safety concerns 03/31/23 Evercore ISI Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI ACHV Achieve Life Sciences $6.03 / +0.02 (+0.33%) 11/16/22 Maxim Achieve Life Sciences price target lowered to $8 from $21 at Maxim 11/15/22 Oppenheimer Achieve Life Sciences price target lowered to $20 from $27 at Oppenheimer OTLK Outlook Therapeutics $1.46 / -0.04 (-2.68%) 04/03/23 Guggenheim Guggenheim starts Outlook Therapeutics at Buy on Lytenava opportunity 04/03/23 Guggenheim Outlook Therapeutics initiated with a Buy at Guggenheim 02/06/23 Cantor Fitzgerald Outlook Therapeutics initiated with an Overweight at Cantor Fitzgerald 10/31/22 BTIG Outlook Therapeutics initiated with a Buy at BTIG RNA OTLK KRYS BPMC ACHV RNA Avidity Biosciences $10.98 / -0.315 (-2.79%) 05/09/23 Avidity Biosciences reports Q1 EPS (74c), consensus (85c) 02/28/23 Avidity Biosciences reports Q4 EPS (88c), consensus (89c) OTLK Outlook Therapeutics $1.46 / -0.04 (-2.68%) 05/15/23 Outlook Therapeutics reports Q2 EPS (3c), consensus (6c) 02/14/23 Outlook Therapeutics reports Q1 EPS (8c), consensus (5c) 12/29/22 Outlook Therapeutics reports 2022 EPS (31c), consensus (31c) KRYS Krystal Biotech $117.51 / -1.31 (-1.10%) 05/08/23 Krystal Biotech reports Q1 EPS ($1.76), consensus ($1.44) 02/27/23 Krystal Biotech reports Q4 EPS ($1.25), consensus ($1.32) BPMC Blueprint Medicines $55.95 / -2.01 (-3.47%) 05/04/23 Blueprint Medicines reports Q1 EPS ($2.15), consensus ($2.67) 02/16/23 Blueprint Medicines reports Q4 EPS ($2.65), consensus ($2.65) ACHV Achieve Life Sciences $6.03 / +0.02 (+0.33%) 05/09/23 Achieve Life Sciences reports Q1 EPS (50c), consensus (69c) 03/16/23 Achieve Life Sciences reports Q4 EPS (83c), consensus (83c) 16 Dec RNA RNA Avidity Biosciences $10.98 / -0.315 (-2.79%) 04/11/23 Drugmakers call for abortion pill ruling reversal, Reuters reports RNA KRYS BPMC ACHV RNA Avidity Biosciences $10.98 / -0.315 (-2.79%) 04/28/23 What You Missed On Wall Street On Friday 04/28/23 What You Missed On Wall Street This Morning 03/31/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/30/23 What You Missed On Wall Street On Thursday KRYS Krystal Biotech $117.51 / -1.31 (-1.10%) 05/24/23 Biotech Alert: Searches spiking for these stocks today 05/22/23 Biotech Alert: Searches spiking for these stocks today 04/06/23 Fly Intel: After-Hours Movers 02/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BPMC Blueprint Medicines $55.95 / -2.01 (-3.47%) 05/22/23 Fly Intel: After-Hours Movers 03/28/23 Fly Intel: After-Hours Movers ACHV Achieve Life Sciences $6.03 / +0.02 (+0.33%) 01/12/23 Biotech Alert: Searches spiking for these stocks today 08/02/23 Biotech/Biopharma 06/02/23 2023 ASCO Annual Meeting 07/11/23 Outlook Therapeutics - OTLK 08/29/23 PDUFA Date for ONS-5010/Lytenava 06/07/23 Achieve Life Sciences, Inc. 06/15/23 Avidity Biosciences, Inc. 06/21/23 Blueprint Medicines Corp.
Initiation	Travere initiated with Outperform, $30 target at TD Cowen » 07:35 05/22/23 05/22 07:35 05/22/23 07:35 TVTX Travere Therapeutics / + TD Cowen analyst Tyler… TD Cowen analyst Tyler Van Buren initiated coverage of Travere Therapeutics with an Outperform rating and $30 price target. The pullback in the shares following the focal segmental glomerulosclerosis miss presents a buying opportunity, the analyst tells investors in a research note. The firm's survey feedback indicates Travere's Filspari IgA nephropathy launch should go very well and the analyst has confidence in management's ability to execute. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly TVTX Travere Therapeutics / + 05/01/23 Travere Therapeutics down 24% at $17.25 after announcing sparsentan study data 05/01/23 Travere Therapeutics' sparsentan study did not achieve primary efficacy 04/02/23 Travere Therapeutics announces interim analysis from Phase 3 PROTECT study 02/17/23 Ligand's partner Travere Therapeutics gets FDA accelerated approval of Filspari TVTX Travere Therapeutics / + 05/22/23 TD Cowen Travere Therapeutics initiated with an Outperform at TD Cowen 05/09/23 Canaccord Travere Therapeutics price target lowered to $37 from $42 at Canaccord 05/05/23 Bryan Garnier Travere Therapeutics upgraded to Neutral from Sell at Bryan Garnier TVTX Travere Therapeutics / + 05/04/23 Travere Therapeutics reports Q2 adjusted EPS (82c), consensus ($1.17) 02/23/23 Travere Therapeutics reports Q4 EPS ($1.03), consensus ($1.07) 01/09/23 Travere Therapeutics sees Q4 net product sales $52M, consensus $57.15 01 Mar TVTX Travere Therapeutics / + 05/02/23 What You Missed On Wall Street On Tuesday 05/02/23 What You Missed On Wall Street This Morning 05/01/23 Fly Intel: After-Hours Movers 02/21/23 What You Missed On Wall Street On Tuesday
Upgrade	Avidity Biosciences upgraded to Outperform from In Line at Evercore ISI » 06:46 05/22/23 05/22 06:46 05/22/23 06:46 RNA Avidity Biosciences $10.82 / +0.115 (+1.07%) Evercore ISI analyst Josh… Evercore ISI analyst Josh Schimmer upgraded Avidity Biosciences to Outperform from In Line with an unchanged price target of $20. The shares have declined to a valuation that the firm believes "adequately reflects" the safety risk for lead program AOC1001 for DM1, while the company recently indicated that the partial hold on AOC1001 is being partially lifted, says the analyst, who sees a path toward "generating a meaningful amount of safety data in a short period of time to better characterize the risk of ischemic events, if any," with AOC1001. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events RNA Avidity Biosciences $10.82 / +0.115 (+1.07%) 05/17/23 Avidity Biosciences: FDA eases partial clinical hold on AOC 1001 04/27/23 Avidity Biosciences announces data from MARINA clinical trial of AOC 1001 04/24/23 Avidity Biosciences granted FDA Fast Track designation to AOC 1044 03/30/23 Avidity Biosciences provides regulatory update on dystrophy candidate AOC 1001 RNA Avidity Biosciences $10.82 / +0.115 (+1.07%) 05/11/23 Wells Fargo Avidity Biosciences price target lowered to $50 from $55 at Wells Fargo 03/31/23 Evercore ISI Avidity Biosciences downgraded to In Line at Evercore on safety concerns 03/31/23 Evercore ISI Avidity Biosciences downgraded to In Line from Outperform at Evercore ISI 02/27/23 Raymond James Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James RNA Avidity Biosciences $10.82 / +0.115 (+1.07%) 05/09/23 Avidity Biosciences reports Q1 EPS (74c), consensus (85c) 02/28/23 Avidity Biosciences reports Q4 EPS (88c), consensus (89c) 16 Dec RNA Avidity Biosciences $10.82 / +0.115 (+1.07%) 04/11/23 Drugmakers call for abortion pill ruling reversal, Reuters reports RNA Avidity Biosciences $10.82 / +0.115 (+1.07%) 04/28/23 What You Missed On Wall Street On Friday 04/28/23 What You Missed On Wall Street This Morning 03/31/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/30/23 What You Missed On Wall Street On Thursday 06/15/23 Avidity Biosciences, Inc.
Initiation	Travere Therapeutics initiated with an Outperform at TD Cowen » 06:08 05/22/23 05/22 06:08 05/22/23 06:08 TVTX Travere Therapeutics $16.45 / -0.18 (-1.08%) TD Cowen analyst Tyler… TD Cowen analyst Tyler Van Buren initiated coverage of Travere Therapeutics with an Outperform rating and $30 price target. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly TVTX Travere Therapeutics $16.45 / -0.18 (-1.08%) 05/01/23 Travere Therapeutics down 24% at $17.25 after announcing sparsentan study data 05/01/23 Travere Therapeutics' sparsentan study did not achieve primary efficacy 04/02/23 Travere Therapeutics announces interim analysis from Phase 3 PROTECT study 02/17/23 Ligand's partner Travere Therapeutics gets FDA accelerated approval of Filspari TVTX Travere Therapeutics $16.45 / -0.18 (-1.08%) 05/09/23 Canaccord Travere Therapeutics price target lowered to $37 from $42 at Canaccord 05/05/23 Bryan Garnier Travere Therapeutics upgraded to Neutral from Sell at Bryan Garnier 05/02/23 Evercore ISI Travere Therapeutics price target lowered to $26 from $36 at Evercore ISI TVTX Travere Therapeutics $16.45 / -0.18 (-1.08%) 05/04/23 Travere Therapeutics reports Q2 adjusted EPS (82c), consensus ($1.17) 02/23/23 Travere Therapeutics reports Q4 EPS ($1.03), consensus ($1.07) 01/09/23 Travere Therapeutics sees Q4 net product sales $52M, consensus $57.15 01 Mar TVTX Travere Therapeutics $16.45 / -0.18 (-1.08%) 05/02/23 What You Missed On Wall Street On Tuesday 05/02/23 What You Missed On Wall Street This Morning 05/01/23 Fly Intel: After-Hours Movers 02/21/23 What You Missed On Wall Street On Tuesday

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial